Benign Prostatic Hyperplasia (Investigational Adjunct)
Investigational adjunct for symptomatic benign prostatic hyperplasia; alpha-blockers, 5-alpha-reductase inhibitors, and minimally invasive surgical therapy remain evidence-based.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for benign prostatic hyperplasia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). Only a single uncontrolled case-series reference exists; there are no randomized controlled trials. Evidence-based first-line therapy per AUA is alpha-blockers (tamsulosin, alfuzosin, silodosin) for symptom relief, 5-alpha-reductase inhibitors (finasteride, dutasteride) for prostate-volume reduction in larger glands, and combination therapy for moderate-to-severe disease. PDE5 inhibitors (tadalafil) help with concurrent erectile dysfunction. Minimally invasive surgical therapies (TURP, holmium laser enucleation, GreenLight laser, UroLift, Rezum, prostatic artery embolization) are highly effective and well-evidenced for medical-refractory disease.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the suprapubic or perineal area for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Temporary worsening of urinary symptoms for 1 to 3 days
- Risk of orthostasis or hypotension if cumulative blood loss is significant on alpha-blocker therapy
- Delay or replacement of evidence-based alpha-blocker, 5-alpha-reductase inhibitor, or minimally invasive surgery
- Failure to address acute retention, recurrent UTI, hematuria, or bladder stones requiring surgical evaluation
- Quién no debería considerar esto
- Patients in acute urinary retention (surgical / catheter management indicated)
- Patients with recurrent UTI attributable to BPH
- Patients with hematuria that has not been worked up
- Patients with bladder stones, hydronephrosis, or renal insufficiency from BPH (surgical indication)
- Patients with suspected prostate cancer (PSA / DRE workup first)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Qué preguntar a su clínico
- What is my IPSS (International Prostate Symptom Score) and bother score?
- Has my PSA been checked, and is prostate cancer ruled out?
- Have I had post-void residual measurement, uroflowmetry, and (where indicated) bladder ultrasound?
- Have I tried alpha-blockers (tamsulosin)? Have 5-alpha-reductase inhibitors been considered if the gland is enlarged?
- Am I a candidate for minimally invasive surgery (UroLift, Rezum, TURP, HoLEP, GreenLight)?
- Where exactly will leeches be placed — NEVER trans-rectal?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Cuándo buscar atención urgente
- Inability to urinate (acute urinary retention — urgent care)
- Visible blood in urine, especially with clots
- Severe lower abdominal pain with distended bladder
- Fever, chills, dysuria, flank pain (UTI or pyelonephritis)
- Sudden urinary leakage (overflow incontinence)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Qué NO significa esto
- It does not shrink the prostate — only 5-alpha-reductase inhibitors have RCT evidence for that, and only in larger glands.
- It does not replace alpha-blockers for symptom relief, which have strong RCT support.
- It does not address acute urinary retention, recurrent UTI, hematuria, or bladder stones, all of which need surgical referral.
- Only one uncontrolled case-series reference exists; benefit is unsupported.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- urogenital
- ICD-10
- N40.0, N40.1, N40.3
- Safety tier
- medium
Evidence Summary
Symptomatic benign prostatic hyperplasia (BPH) presents with lower urinary tract symptoms (LUTS): frequency, urgency, weak stream, nocturia, and incomplete emptying. AUA evidence-based first-line pharmacotherapy is alpha-blockers (tamsulosin, alfuzosin) for symptom relief, 5-alpha-reductase inhibitors (finasteride, dutasteride) for gland-volume reduction in larger prostates, combination therapy for moderate-severe disease, and PDE5 inhibitors (tadalafil) for concurrent erectile dysfunction. Minimally invasive surgical therapy (TURP, GreenLight laser, UroLift, Rezum) is highly effective for medical-refractory disease. No published controlled trials or case series of hirudotherapy exist for benign prostatic hyperplasia; any use is investigational only, and the mechanism for any deep prostatic effect from skin placement is speculative.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Acute urinary retention (surgical referral)
- Recurrent UTI from BPH
- Hematuria not worked up
- Bladder stones, hydronephrosis, or renal insufficiency from BPH (surgical indication)
- Suspicion of prostate cancer (PSA, DRE workup first)
Related Conditions
Peyronie's Disease (Stable Phase)
Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)
Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.
Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.